| Name | Title | Contact Details |
|---|---|---|
Dan O'Neill |
Vice President of Information Technology | Profile |
Jeff Hrkach |
Senior Vice President of Technology Development | Profile |
Checkerspot is a design-centric materials company enabling ultra-high performance consumer products.
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women`s health diseases and other endocrine-related disorders. Myovant`s lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant is in the process of initiating five international Phase 3 clinical trials for relugolix, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women`s health and endocrine-related disorders.
3DBio is the first company implanting personalized 3D-printed living tissues in patients. #3DBioPrinting​ #3DBio
Strang Cancer Prevention Institute is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ambient Eco Group is a Golden, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.